• SGC-CBP30: Advancing CREBBP/EP300 Bromodomain Inhibitor Work

  2026-05-07

  SGC-CBP30 empowers epigenetics and cancer biology research by enabling precise, reproducible modulation of transcriptional coactivators CREBBP and EP300. Applied in super-enhancer hijacking studies, it provides researchers with a robust workflow for dissecting transcriptional regulation and tumor progression mechanisms.

• Kanamycin Sulfate: Precision Use in Microbiota and Resistanc

  2026-05-06

  Discover how Kanamycin Sulfate, a water-soluble antibiotic, enables advanced microbiology and antibiotic resistance research. This article uniquely focuses on its value in microbiota modulation and experimental rigor, with insights from the latest translational studies.

• ALDH2 Activation Promotes Cardiomyocyte Proliferation in Hea

  2026-05-06

  The referenced study demonstrates that activation of aldehyde dehydrogenase 2 (ALDH2) significantly enhances cardiomyocyte proliferation and delays the progression of heart failure in a mouse model of ventricular pressure overload. This work positions ALDH2 as a promising target for regenerative strategies in cardiac disease, with implications for designing therapies that address the limited regenerative capacity of adult mammalian hearts.

• Olaparib (AZD2281) in Cancer Research: Protocols & Advances

  2026-05-05

  Olaparib (AZD2281) empowers precise DNA damage response assays and tumor radiosensitization studies, especially in BRCA-deficient cancer models. This guide distills advanced workflows, troubleshooting tactics, and translational innovations from recent nanodelivery breakthroughs to accelerate impactful cancer research.

• Kanamycin Sulfate (A2516): Robust Solutions for Cell Assays

  2026-05-05

  This article delivers a scenario-driven, evidence-based guide to overcoming common laboratory challenges in cell viability and cytotoxicity workflows using Kanamycin Sulfate (SKU A2516). It compares real-world assay pitfalls, provides actionable protocol parameters, and demonstrates how APExBIO's Kanamycin Sulfate ensures reproducibility and reliability for contemporary biomedical research.

• Chloroquine Diphosphate in Autophagy Assays: Protocols & Pit

  2026-05-04

  Chloroquine diphosphate stands out as a dual-function TLR7/9 inhibitor and autophagy modulator, enabling precise modulation of cell fate in cancer research. This article delivers evidence-backed protocols, troubleshooting strategies, and advanced applications that maximize reproducibility and translational impact—anchored by APExBIO’s trusted formulation.

• Kanamycin Sulfate: Applied Workflows for Microbiology & Resi

  2026-05-04

  Kanamycin Sulfate from APExBIO delivers high-purity, water-soluble antibiotic performance tailored for modern microbiology and antibiotic resistance workflows. This article translates quantitative literature findings and real-world troubleshooting into actionable protocols for robust cell selection, protein synthesis inhibition, and anti-infection studies.

• Flubendazole: Strategic Autophagy Modulation in Cancer Model

  2026-05-03

  This thought-leadership article explores how Flubendazole (methyl N-[6-(4-fluorobenzoyl)-1H-benzimidazol-2-yl]carbamate) unlocks novel opportunities for translational researchers investigating autophagy signaling in cancer biology. Drawing on new mechanistic findings and workflow-oriented protocol advice, we illuminate strategic considerations for deploying this APExBIO compound in advanced breast cancer models and beyond.

• Methyl-β-cyclodextrin: Technical Use in Membrane Cholesterol

  2026-05-02

  Methyl-β-cyclodextrin (SKU C6939) is employed for membrane cholesterol extraction, lipid raft disruption, and modulation of membrane fluidity in biochemical and cell-based research. It is intended exclusively for laboratory research and is not suitable for clinical or diagnostic procedures.

• Carbon-Ion Radiotherapy Promotes Ferroptosis in Gastric Canc

  2026-05-02

  Wang and Cai (2025) reveal that carbon-ion radiotherapy (CIRT) suppresses gastric cancer progression by inducing ferroptosis and promoting M1 macrophage polarization via DHODH downregulation. These findings clarify the mechanistic advantages of CIRT and suggest DHODH as a promising therapeutic target, with implications for improving radiotherapy resistance in advanced gastric cancer.

• QNZ (EVP4593): Precision NF-κB Inhibition for Neurodegenerat

  2026-05-01

  QNZ (EVP4593) stands apart as a nanomolar-potency NF-κB pathway inhibitor, purpose-built for dissecting inflammation and neurodegenerative mechanisms. This article delivers actionable workflow protocols, troubleshooting insights, and research-driven optimizations for maximizing QNZ’s translational value in disease modeling.

• Micro- and Nanoplastics Heighten Pulmonary Fibrosis Risk in

  2026-04-30

  This study systematically compares the pulmonary toxicity of microplastics and nanoplastics (PS, PE, PP) in vivo and in vitro, revealing that particle size and polymer type critically modulate fibrogenic and inflammatory responses. Mechanistic insights implicate the FXR-YAP1 axis in mediating these effects, with polystyrene nanoplastics exhibiting the highest toxicity, informing both environmental risk assessments and molecular toxicology research.

• HyperScribe T7 High Yield Cy5 RNA Labeling Kit: Advanced Pro

  2026-04-30

  The HyperScribe T7 High Yield Cy5 RNA Labeling Kit streamlines fluorescent RNA probe synthesis for in situ and Northern blot hybridizations, delivering high labeling efficiency and reproducibility. Its optimized workflow and customizable Cy5-UTP incorporation empower researchers to tackle complex RNA–protein interaction studies, such as those revealing viral assembly mechanisms.

• PreScission Protease: Enabling Next-Gen Condensate Biology

  2026-04-29

  Discover how PreScission Protease (PSP) advances biomolecular condensate research and protein purification. This in-depth analysis explores PSP's HRV 3C protease mechanism, unique cold-active properties, and practical assay guidance, highlighting innovations for molecular biology workflows.

• BCL-XL Inhibitor A-1155463: Applied Workflows in Cancer Rese

  2026-04-29

  The selective BCL-XL inhibitor A-1155463 enables precise apoptosis induction in BCL-XL-dependent cancer models, outperforming earlier tools in both potency and selectivity. This guide unpacks optimized workflows, troubleshooting, and direct applications for overcoming drug resistance in solid tumors and hematological malignancies.

15915 records 1/1061 page Next 12345 下5页 Last page